Online inquiry

IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7939MR)

This product GTTS-WQ7939MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ICOS gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_012092.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29851
UniProt ID Q9Y6W8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7939MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9830MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ8356MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA hPAM4
GTTS-WQ5579MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP7766
GTTS-WQ3405MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aALB03
GTTS-WQ2378MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 102
GTTS-WQ11397MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ12004MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ1030MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-399
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW